Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Atopic Hand and Foot Dermatitis (LIBERTY-AD-HAFT)
NCT04417894Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at 16 weeks. Started Apr 2021; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04417894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04417894.